title: A Multicenter, Open-label, Randomized, Active-controlled, Parallel Group, Pivotal Study to Investigate the Efficacy, Safety and Tolerability, and Pharmacokinetics of Murepavadin Combined With One Anti-pseudomonal Antibiotic Versus Two Anti-pseudomonal Antibiotics in Adult Subjects With Ventilator-associated Bacterial Pneumonia Suspected or Confirmed to be Due to Pseudomonas Aeruginosa

acronym: PRISM-MDR

summary: This is a phase 3, multicenter, open-label, randomized active-controlled, parallel group to investigate the efficacy, safety and tolerability, and pharmacokinetics of intravenous murepavadin combined with of one anti-pseudononas antibiotic with that of two anti-pseudomonas antibiotics in the treatment of ventilator-associated bacterial pneumonia (VABP) in adult subjects.

lead_sponsor: Polyphor Ltd.

location_country:
Brazil
South Africa
Mexico
Croatia
France
Greece
Israel
Thailand
Hungary
Spain
Estonia
United States
Korea, Republic of

location_facility:
Research site 3
Research Site 3
Research Site
Research Site 1
Research site
Research site 1
Reasearch site
Research site 2
Research Site 2


type: EudraCT Number

title: A 28-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center, Study in Recombinant Human Erythropoietin (rhEPO) naïve Non-dialysis Participants With Anemia Associated With Chronic Kidney Disease to Evaluate the Efficacy, Safety and Effects on Quality of Life of Daprodustat Compared to Placebo

summary: The purpose of this multi-center study in non-dialysis participants with anemia associated with CKD is to evaluate safety, efficacy and quality of life of daprodustat compared to placebo.

study_start_date_type: Actual

status: Completed

study_completion_date_type: Actual

study_type: Interventional

design_allocation: Randomized

primary_purpose: Treatment

enrollment_type: Actual

ipd_sharing: Yes

ipd_sharing_description: IPD for this study will be made available via the Clinical Study Data Request site.

lead_sponsor: GlaxoSmithKline

location_country:
Italy
Brazil
United States
Mexico
France
Poland
Romania
Argentina
Australia
Russian Federation
Spain
Canada
United Kingdom
Korea, Republic of

intervention_type: Drug

lead_sponsor_type: industriel

status_simplified: Completed


ReferenceType: derived

ReferenceCitation: Pérez-García J, Soberino J, Racca F, Gion M, Stradella A, Cortés J. Atezolizumab in the treatment of metastatic triple-negative breast cancer. Expert Opin Biol Ther. 2020 Sep;20(9):981-989. doi: 10.1080/14712598.2020.1769063. Epub 2020 May 25. Review.

name: IOB Institute of Oncology, Quironsalud Group, Madrid & Barcelona, Spain

name: Medica Scientia Innovation Research (MedSIR), Barcelona, Spain

family: Pérez-García

full_name: José Pérez-García

given: José

sequence: first

family: Soberino

full_name: Jesús Soberino

given: Jesús

sequence: additional

family: Racca

full_name: Fabricio Racca

given: Fabricio

name: Hospital Universitario Ramón y Cajal, Madrid, Spain

family: Gion

full_name: María Gion

given: María

name: Institut Català d’Oncologia, Hospitalet de Llobregat, Barcelona, Spain

family: Stradella

full_name: Agostina Stradella

given: Agostina

name: Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain

family: Cortés

full_name: Javier Cortés

given: Javier

bso_classification: Medical research

datasource: user

genre: journal-article

genre_raw: journal-article

journal_name: Expert Opinion on Biological Therapy

publisher: Informa UK Limited

publisher_dissemination: Informa

publisher_group: Informa

publisher_normalized: Informa

ReferenceCitation: Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549.

name: From Barts Cancer Institute, Queen Mary University of London, London (P.S.); International Oncology Bureau Institute of Oncology, Quirón Group, Madrid, and Vall d’Hebron Institute of Oncology, Barcelona (J.C.) — both in Spain; Yale School of Medicine, Yale Cancer Center, New Haven, CT (L.P.); Cedars-Sinai Medical Center, Los Angeles (H.M.); Kliniken Essen-Mitte, Essen (S.K.), the Institute of Pathology, Philipps-University Marburg and University of Marburg, Marburg (C.D.), the Breast Center, Department...

family: Schmid

full_name: Peter Schmid

given: Peter

family: Cortes

full_name: Javier Cortes

family: Pusztai

full_name: Lajos Pusztai

given: Lajos

family: McArthur

full_name: Heather McArthur

given: Heather

family: Kümmel

full_name: Sherko Kümmel

given: Sherko

family: Bergh

full_name: Jonas Bergh

given: Jonas

family: Denkert

full_name: Carsten Denkert

given: Carsten

family: Park

full_name: Yeon Hee Park

given: Yeon Hee

family: Hui

full_name: Rina Hui

given: Rina

family: Harbeck

full_name: Nadia Harbeck

given: Nadia

family: Takahashi

full_name: Masato Takahashi

given: Masato

family: Foukakis

full_name: Theodoros Foukakis

given: Theodoros

family: Fasching

full_name: Peter A. Fasching

given: Peter A.

family: Cardoso

full_name: Fatima Cardoso

given: Fatima

family: Untch

full_name: Michael Untch

given: Michael

family: Jia

full_name: Liyi Jia

given: Liyi

family: Karantza

title: Pembrolizumab for Early Triple-Negative Breast Cancer

location_country:
Australia
Russian Federation
Taiwan
France
Japan
Poland
Canada
Korea, Republic of
Colombia
Sweden
Singapore
Ireland
Portugal
United States
Germany
United Kingdom
Italy
Brazil
Israel
Spain
Turkey

acronym: Evaluate chemotherapy plus MK-3475 vs chemotherapy plus placebo and  MK-3475 vs placebo  for TNBC

location_facility: Cedars Sinai Medical Center ( Site 0091)

location_facility: Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1102)

location_facility: Royal Brisbane and Women s Hospital ( Site 2003)

location_facility: Goshen Center for Cancer Care ( Site 0010)

location_facility: Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 1912)

location_facility: Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 1803)

location_facility: North Shore University Health System ( Site 0081)

location_facility: Acibadem Altunizade Hastanesi ( Site 1900)

location_facility: National Cancer Center Hospital ( Site 2500)

location_facility: St Vincents University Hospital ( Site 1550)

location_facility: Mazowiecki Szpital Onkologiczny ( Site 1713)

location_facility: Centrum Onkologii Instytut im. Marii Sklodowskiej Curie ( Site 1719)

location_facility: CHU de Quebec Universite Laval - Hopital du Saint-Sacrement ( Site 0104)

location_facility: The University of Chicago Medical Center ( Site 0047)

location_facility: TriHealth Cancer Institute-Good Samaritan Hospital ( Site 0044)

location_facility: Szpital Morski im. PCK. Szpitale Pomorskie Sp. Z o.o ( Site 1701)

location_facility: Hospital Nossa Senhora da Conceicao ( Site 0203)

location_facility: Instituto De Cancerologia S.A. ( Site 0406)

location_facility: CHU de la Miletrie Poitiers ( Site 0913)

location_facility: Oncologos del Occidente S.A. ( Site 0405)

location_facility: St John of God Subiaco Hospital ( Site 2006)

location_facility: Providence Portland Medical Center ( Site 0052)

location_facility: Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0106)

location_facility: Universitaets-Frauenklinik Tuebingen ( Site 1003)

location_facility: Houston Methodist Cancer Center ( Site 0013)

location_facility: Orchard Healthcare Research Inc. ( Site 0049)

location_facility: Koo Foundation Sun Yat-Sen Cancer Center ( Site 2304)

location_facility: National Cancer Center Hospital East ( Site 2518)

location_facility: Virginia G. Piper Cancer Center Pharmacy - Scottsdale Healthcare ( Site 0089)

location_facility: Virginia Oncology Associates ( Site 8000)

location_facility: Parkland Health and Hospital System ( Site 0093)

location_facility: Hopital Diaconesses Croix Saint Simon ( Site 0905)

location_facility: Instituto Nacional de Cancerologia [Bogota-Colombia] ( Site 0403)

location_facility: Chelyabinsk Regional Clinical Oncological Dispensary ( Site 1805)

location_facility: National Hospital Organization Hokkaido Cancer Center ( Site 2512)

location_facility: Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 1806)

location_facility: Karolinska Universitetssjukhuset Solna ( Site 1404)

location_facility: Rutgers Cancer Institute of New Jersey ( Site 0073)

location_facility: Universitaetsklinik und Poliklinik Halle/Saale ( Site 1008)

location_facility: The Cancer Institute Hospital of JFCR ( Site 2509)

location_facility: Medical Oncology Associates (Summit Cancer Centers) ( Site 0014)

location_facility: Centrum Onkologii Instytut im. Marii Skłodowskiej Curie ( Site 1717)

location_facility: Instituto do Cancer de Sao Paulo - ICESP ( Site 0211)

location_facility: St.Luke's International Hospital ( Site 2511)

location_facility: Polyclinique Bordeaux Nord Aquitaine ( Site 0911)

location_facility: Social medical corporation Hakuaikai Sagara Hospital ( Site 2508)

location_facility: Universitaetsklinikum Erlangen ( Site 1001)

location_facility: Trakya University Medical Faculty Balkan Oncology Hospital ( Site 1901)

location_facility: Izmir Medical Park Hospital Department of Medical Oncology ( Site 1907)

location_facility: New England Cancer Specialists ( Site 0005)

location_facility: Ospedale San Luca, AZIENDA USL2 TOSCANA NORD OVEST ( Site 1105)

location_facility: GBU RO Regional Clinical Oncological Dispensary ( Site 1808)

location_facility: UOPECCAN - Uniao Oeste Paranaense de Estudos e Combate ao Cancer ( Site 0206)

location_facility: Taipei Veterans General Hospital ( Site 2302)

location_facility: Aichi Cancer Center Hospital ( Site 2502)

location_facility: Ospedale Civile di Macerata ( Site 1104)

location_facility: Institut Claudius Regaud IUCT Oncopole ( Site 0914)

location_facility: Colchester General Hospital ( Site 1508)

location_facility: Antalya Memorial Hospital Department of Medical Oncology ( Site 1908)

location_facility: Arkhangelsk Clinical Oncological Dispensary ( Site 1810)

location_facility: University of Iowa Hospital and Clinics ( Site 0038)

location_facility: National Taiwan University Hospital ( Site 2301)

location_facility: Texas Oncology-San Antonio Northeast ( Site 8012)

location_facility: Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 1804)

location_facility: The Ottawa Hospital - Cancer Care ( Site 0100)

location_facility: Abdurrahman Yurtaslan Oncology Training and Research Hospital ( Site 1909)

location_facility: University of Colorado Cancer Center ( Site 0021)

location_facility: Instituto do Cancer do Ceara ( Site 0205)

location_facility: Minnesota Oncology Hematology, PA ( Site 8013)

location_facility: Nyack Hospital Infusion Center ( Site 0059)

location_facility: Hospital Universitario San Ignacio ( Site 0401)

location_facility: Hospital Universitario Reina Sofia ( Site 1304)

location_facility: Hospital Universitario Ramon y Cajal ( Site 1300)

location_facility: Istituto Scientifico Romagnolo per Studio e Cura Tumori IRST ( Site 1101)

location_facility: Istituto Europeo di Oncologia ( Site 1106)

location_facility: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia ( Site 1103)

location_facility: Nottingham University Hospitals NHS Trust ( Site 1505)

location_facility: Kadlec Clinic Hematology and Oncology ( Site 0087)

location_facility: National Hospital Organization Osaka National Hospital ( Site 2505)

location_facility: Ege University Medical Faculty Tulay Aktas Oncology Hospital ( Site 1905)

location_facility: Instituto Oncologico Baselga.Hospital Quiron. ( Site 1312)

location_facility: Seoul National University Hospital ( Site 2101)

location_facility: Baskent Unıversity Adana Kısla Hospital ( Site 1903)

location_facility: HELIOS Klinikum Berlin-Buch ( Site 1005)

location_facility: Universitaetsklinikum Hamburg-Eppendorf ( Site 1007)

location_facility: UT Southwestern Medical Center ( Site 0030)

location_facility: Hadassah Ein Karem - Sharett Institute of Oncology ( Site 1600)

location_facility: YVMH dba Vrigina Mason Memorial/North Star Lodge Cancer Center ( Site 8004)

location_facility: Shizuoka Cancer Center Hospital and Research Institute ( Site 2514)

location_facility: Virginia Cancer Specialists, PC ( Site 8009)

location_facility: Ozel Medicana International Ankara Hastanesi ( Site 1915)

location_facility: National Cancer Centre Singapore ( Site 2600)

location_facility: Adana Acıbadem Hospital Department of Medical Oncology ( Site 1906)

location_facility: Texas Oncology-Memorial City ( Site 8003)

location_facility: Kumamoto University Hospital ( Site 2515)

location_facility: St. Marianna University School of Medicine Hospital ( Site 2516)

location_facility: Severance Hospital Yonsei University Health System ( Site 2100)

location_facility: Hospital General Universitari Vall d Hebron ( Site 1301)

location_facility: Samsun Ondokuz Mayıs Universitesi Tıp Fakultesi Hastanesi ( Site 1910)

location_facility: Hospital Clinico Univ de Valencia ( Site 1313)

location_facility: Princess Margaret Cancer Centre ( Site 0103)

location_facility: Linkou Chang Gung Memorial Hospital ( Site 2300)

location_facility: Instituto Portugues de Oncologia Do Porto Francisco Gentil E.P.E. ( Site 2446)

location_facility: Hyogo College of Medicine Hospital ( Site 2506)

location_facility: Royal Cornwall Hospitals NHS Trust ( Site 1504)

location_facility: Peninsula Cancer Institute, LLC ( Site 0041)

location_facility: Univ of Miami-Sylvester Comprehensive Cancer Center- Kendall satellite ( Site 0079)

location_facility: Dolnoslaskie Centrum Onkologii. ( Site 1702)

location_facility: Hospital Sao Lucas da PUCRS ( Site 0200)

location_facility: Oncology Hematology Care, Inc. ( Site 8011)

location_facility: Hospital Universitario Virgen del Rocio ( Site 1314)

location_facility: Centrum Onkologii Ziemi Lubelskiej im. sw. Jana z Dukli ( Site 1700)

location_facility: Universidade de Caxias do Sul ( Site 0201)

location_facility: Saitama Medical University International Medical Center ( Site 2513)

location_facility: Arizona Oncology Associates PC- HOPE ( Site 8001)

location_facility: Northwest Cancer Specialists, P.C. ( Site 8008)

location_facility: Seattle Cancer Care Alliance ( Site 0068)

location_facility: Linkopings Universitetssjukhus ( Site 1402)

location_facility: Texas Oncology-Austin Central ( Site 8005)

location_facility: Bon Secours Cancer Institute Medical Oncology at St. Mary's ( Site 0033)

location_facility: Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto ( Site 0208)

location_facility: Hospital de Santa Maria, E.P.E. ( Site 2445)

location_facility: National Cheng Kung University Hospital ( Site 2305)

location_facility: Klinikum der Universit. Muenchen ( Site 1002)

location_facility: Complejo Hospitalario Universitario de Santiago ( Site 1308)

location_facility: Russian Oncological Research Center n.a. N.N.Blokhin of MoH ( Site 1801)

location_facility: Norrlands Universitetssjukhus ( Site 1401)

location_facility: Hiroshima City Hiroshima Citizens Hospital ( Site 2501)

location_facility: Yale University School of Medicine ( Site 0054)

location_facility: The James Cook University Hospital ( Site 1515)

location_facility: Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 1708)

location_facility: Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 1712)

location_facility: Texas Oncology-Baylor Charles A. Sammons Cancer Center ( Site 8006)

location_facility: İstanbul University Cerrahpaşa Medical Faculty ( Site 1904)

title: A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)

summary:
The purpose of this study is to evaluate the efficacy and safety of pembrolizumab (MK-3475) plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy and pembrolizumab vs placebo as adjuvant therapy in participants who have triple negative breast cancer (TNBC).

After a screening phase of approximately 28 days, each participant will receive neoadjuvant study treatment (Pembrolizumab + Chemotherapy OR Placebo + Chemotherapy) based on the randomization schedule for approximately 24 weeks (8 cycles). Each participant will then undergo definitive surgery 3-6 weeks after conclusion of the last cycle of the neoadjuvant study treatment. After definitive surgery, each participant will receive adjuvant study treatment (Pembrolizumab OR Placebo) for approximately 27 weeks (9 cycles). Following adjuvant study treatment, each participant will be monitored for safety, survival and disease recurrence.

The primary study hypothesis is that pembrolizumab is superior to placebo, in combination with chemotherapy, as measured by the rate of Pathological Complete Response (pCR) and/or Event-free Survival (EFS), in participants with locally advanced TNBC.


title: A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma

summary: This is a randomized, open-label, multi-center, phase 3 study of napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine for adult patients with Metastatic Pancreatic Ductal Adenocarcinoma.

lead_sponsor: Sumitomo Dainippon Pharma Oncology, Inc

location_country:
Italy
Austria
United States
Netherlands
Spain
Germany
France
Czechia
Japan
Poland
Singapore
Australia
Belgium
Russian Federation
China
Canada
Korea, Republic of
Taiwan
Portugal
Ukraine

location_facility: Mercy Clinic Oncology and Hematology - McAuley

location_facility: Hospital Universitario Germans Trias i Pujol

location_facility: Green Bay Oncology, Ltd. - West Green Bay

location_facility: The 81 Hospital of the Chinese Peoples Liberation Army

location_facility: Georgetown University Medical Center (GUMC)

location_facility: University of Toronto - St. Michael's Hospital

location_facility: Cancer Center of Guangzhou Medical University

location_facility: Oncology and Hematology Associates of Southwest Virginia

location_facility: UCLA Medical Center Santa Monica Hematology And Oncology

location_facility: Landeskrankenhaus Medical University Innsbruck

location_facility: Hospital Clínico y Provincial de Barcelona

location_facility: FSBI "Russian Research Centre of Radiology and Surgical Technologies"

location_facility: Indiana University - Melvin and Bren Simon Cancer

location_facility: Hospital Universitario Fundacion Alcorcon

location_facility: Arkhangelsk Regional Clinical Oncology Dispensary

location_facility: North Shore Hematology Oncology Associates PC

location_facility: Weill Cornell Medicine/ NewYork-Presbyterian

location_facility: Ren Ji Hospital Shanghai Jiaotong University School of Medicine

location_facility: Maine Center for Cancer Medicine - Scarborough

location_facility: The Affiliated Hospital of Qingdao University

location_facility: Gabrail Cancer Center (GCC) - Canton Facility

location_facility: Fakultni nemocnice Brno Interni hematoonkologicka klinika

location_facility: Budgetary Healthcare Institution of Omsk Region

location_facility: Norwalk Hospital The C Anthony and Jean Whittingham Cancer Center

location_facility: MultiCare Institute for Research and Innovation

location_facility: Winship Cancer Institute of Emory University

location_facility: Hematology Oncology Associates of Central New York

location_facility: The Atlantic Clinical Cancer Research Unit (ACCRU)

location_facility: Chonnam National University Hwasun Hospital

location_facility: Aurora St. Luke's Medical Center - Vince Lombardi

location_facility: The First Affiliated Hospital of Soochow University

location_facility: Kaiser Permanente - Vallejo Medical Center

location_facility: West Virginia University Mary Babb Randolph Cancer Center (MBRCC)

location_facility: Universitatsklinik far Innere Medizin III

location_facility: St.Petersburg Medical Universitet n.a. I.P. Pavlov

location_facility: Fox Chase Cancer Center (FCCC) - Philadelphia

location_facility: Los Angeles Hematology Oncology Medical Group

location_facility: National Research Mordovia State University

location_facility: UNC Chapel Hill / Lineberger Comprehensive Cancer

location_facility: The First Affiliated Hospital of Xian Jiao Tong University

location_facility: Washington University School of Medicine

location_facility: Charleston Hematology Oncology Associates

location_facility: UNM Cancer Research and Treatment Center

location_facility: Seoul national University Bundang Hospital

location_facility: Kursk Regional Clinical Oncology Dispensary

location_facility: Bon Secours Cancer Institute Medical Oncology

location_facility: Klinikum Oldenburg AöR - UK für Innere Medizin

location_facility: Northwestern Medicine Regional Medical Group

location_facility: The Second Affiliated Hospital of Anhui Medical University

location_facility: Louisiana Hematology Oncology Associates (LHOA)

location_facility: General Hospital of Ningxia Medical University

location_facility: Medical University of South Carolina (MUSC)

location_facility: Metro MN Clinical Oncology Research Consortium

location_facility: Harbin Medical University Cancer Hospital

location_facility: Tianjin Medical University Cancer Institute & Hospital

location_facility: Penn State Milton S. Hershey Medical Center

location_facility: The Second Affiliated Hospital Zhejiang University

location_facility: The Center for Cancer and Blood Disorders

location_facility: The First Affiliated Hospital of Anhui Medical University

location_facility: Istituto Ricerca e la Cura del Cancro (IRCC)

location_facility: Hospital Regional Universitario de Málaga

location_facility: Torrance Health Association DBA Torrance Memorial

location_facility: University of Missouri - Ellis Fischel Cancer Cent

location_facility: Zaytsev Institute General and Urgent Surgery of National Academy Medical Science of Ukraine

location_facility: UF Health Cancer Center - Orlando Health

location_facility: Kaiser Permanente - Westside Medical Office

location_facility: N.N. Blokhin Russian Cancer Research Center

location_facility: Florida Cancer Specialists & Research Institute

location_facility: HSHS St. Vincent Hospital Regional Cancer Center

location_facility: Fujian Medical University Union Hospital

location_facility: The First Affiliated Hospital Zhejiang University

location_facility: Railway Clinical Hospital on station Chelyabinsk

location_facility: Sir Run Shaw Hospital School of Medicine Zhejiang University

location_facility: Orenburg Regional Clinical Oncology Dispensary


title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease

summary:
The purpose of study is to test the effect of an experimental medication GED-0301(mongersen) and evaluate its safety in patients (≥ 12 years of age) with active Crohn's disease. The study will test GED-0301 compare to placebo for 12 weeks. The study treatment is blinded which means that patients and the study doctor will not know which treatment has been assigned. Patients in this study will be allowed treatment with stable doses of oral aminosalicylates, oral corticosteroids, immunosupressants and antibiotics for the treatment of Crohn's disease. Adolescent patients will also be allowed treatment with stable doses of exclusive enteral nutrition and growth hormone.

All patients who complete the study will have the option to enter a long term active treatment study.

study_start_date_type: Anticipated

status: Withdrawn

study_completion_date_type: Anticipated

lead_sponsor: Celgene

location_country:
Finland
Greece
Romania
Australia
Belgium
Russian Federation
Denmark
Ukraine
Croatia
France
Poland
Slovakia
Canada
Korea, Republic of
Sweden
Switzerland
Netherlands
Hungary
Portugal
United States
Germany
United Kingdom
Italy
Austria
Serbia
Czechia
Israel
Spain
Turkey
Latvia

location_facility: Haydarpasa Numune Training and Research Hospital

location_facility: Centro Hospitalar do Alto Minho - Unidade Local de Saúde do Alto Minho, EPE

location_facility: The Catholic University of Korea, St. Vincent's Hospital

location_facility: Ternopil City Communal Emergency Medical Care Hospital

location_facility: Oklahoma Foundation for Digestive Research

location_facility: Medical Research Center of Connecticut LLC

location_facility: Marmara University Pendik Training and Research Hospital

location_facility: The Feinstein Institute for Medical Research PRIME

location_facility: Basingstoke and North Hampshire Hospital

location_facility: Istanbul University Cerrahpasa Medical Faculty

location_facility: NonState Healthcare Institution Central Clinical Hospital, Samara station JSC Russian Railways

location_facility: University of Utah Division of Gastroenterology

location_facility: Azienda Ospedaliera Universitaria Policlinico Sant Orsola Malpighi

location_facility: Swedish Medical Center Cancer Institute Research

location_facility: Gastroenterology Associates of Western Michigan PLC

location_facility: University of Wisconsin Hospital and Clinics

location_facility: CHA Bundang Medical Center CHA University

location_facility: Johns Hopkins University School of Medicine

location_facility: Premier Medical Group of the Hudson Valley PC

location_facility: SRI of Invalid Rehabilitation EST Complex of Vinnytsia M.I.Pyrogov NMU MOHU

location_facility: University of Oklahoma Health Sciences Center

location_facility: Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont Szent-Gyorgyi Albert TE AOK Borgyogy

location_facility: Crohn-Colitis Zentrum Bern Gemeinschaftspraxis Balsiger Seibold und Partner

location_facility: Via Christi Research a division of Via Christi Hospitals Wichita Inc

location_facility: CI of SRC Sumy RCH Dept of Rheumatology Sumy SU MI

location_facility: Gastroenterology Associates of Tidewater

location_facility: Istanbul Medeniyet Uni Goztepe Training&Res Hosp

location_facility: University of California at San Francisco (PARENT)

location_facility: CI Zaporizhzhia Regional Clinical Hospital of ZRC

location_facility: Kocaeli Derince Training and Research Hospital

location_facility: Fondazione IRCCS CA Granda Ospedale Maggiore Policlinico

location_facility: Hospital General Universitario Gregorio Maranon

location_facility: NYU Langone Long Island Clinical Research Associates

location_facility: Azienda Ospedaliero Universitaria Pisana

location_facility: Texas Digestive Disease Consultants - Southlake

location_facility: Northwestern University-Feinberg School of Medicine

location_facility: Northshore University Healthsystem Research Institute

location_facility: Azienda Ospedaliera Universitaria Policlinico Tor Vergata

location_facility: University of North Carolina at Chapel Hill

location_facility: SP ZOZ Wojewodzki Szpital Zespolony im. J. Sniadeckiego

location_facility: FSBI Scientific Research Institute of Physyology and Basic Medicine under the SB of RAMS

location_facility: Seoul National University Bundang Hospital

location_facility: Azienda Ospedaliera San Camillo Forlanini

location_facility: University of Southern California Medical Center

location_facility: Hospital General Universitario de Alicante

location_facility: Nottingham University Hospitals Queens Medical Centre

location_facility: University of Pennsylvania School of Medicine

location_facility: Azienda Ospedaliera Universitaria OO. RR. S. Giovanni di Dio e Ruggi dAragona

location_facility: Hospital da Senhora da Oliveira Guimaraes

location_facility: SI Branch CH of Zaporizhzhia Station-2 of SE Prydniprovska Railway Dept of Surgery Zaporizhzhia SMU

location_facility: University of Texas Health Science Center at Houston

location_facility: Riga East Clinical University Hospital clinic Gailezers

location_facility: SBEIHPE Novosibirsk State Medical University

location_facility: Treatment-Diagnostic Center of Private Enterprise of PMF Atsynus

location_facility: Centre de sante et de services sociaux Champlain Charles Le Moyne

location_facility: Universitaetsklinikum Schleswig Holstein Campus Kiel

location_facility: Royal Adelaide Hospital Institute of Medical and Veterinary Science

location_facility: LKH - Universitätsklinikum der PMU Salzburg

location_facility: Penn State University Milton S Hershey Medical Center

location_facility: University of Washington School of Medicine

location_facility: Universitaetsklinikum EssenZentrum fuer Innere Medizin

location_facility: Yonsei University Wonju Severance Christian Hospital

location_facility: Asheville Gastroenterology Associates, P.A.

location_facility: Clinsante S.C. Osrodek Badan Klinicznych

location_facility: University Hospitals Cleveland Medical Center

location_facility: North Shore-LIJ Health System-Division of Rheumatology

location_facility: Clinical Research Institute of Michigan, LLC

status_simplified: Unknown


title: A Phase 2 Open-Label Study to Determine the Effect of Blinatumomab on Minimal Residual Disease in Subjects With High-risk Diffuse Large B-cell Lymphoma Post-autologous Hematopoietic Stem-cell Transplantation.

summary: The study will estimate the MRD-negative response rate after treatment with blinatumomab in subjects with high-risk DLBCL who are MRD-positive following aHSCT. The clinical hypothesis is that the MRD-negative response rate will be greater than 10%. Achieving an MRD-negative response rate of 30% would be of scientific and clinical interest.

status: Terminated

ipd_sharing_description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

lead_sponsor: Amgen

location_country:
Italy
Switzerland
France
Greece
Belgium
Australia
United States


type: Other Identifier

title: A Study of Enfortumab Vedotin (ASG-22CE) as Monotherapy or in Combination With Other Anticancer Therapies for the Treatment of Urothelial Cancer

summary: This study will test an experimental drug (enfortumab vedotin) alone and with different combinations of anticancer therapies. Pembrolizumab is an immune checkpoint inhibitor (CPI) that is used to treat patients with cancer of the urinary system (urothelial cancer). This type of cancer includes cancer of the bladder, renal pelvis, ureter or urethra. Some parts of the study will look at locally advanced or metastatic urothelial cancer (la/mUC), which means the cancer has spread to nearby tissues or to other areas of the body. Other parts of the study will look at muscle-invasive bladder cancer (MIBC), which is cancer at an earlier stage that has spread into the muscle wall of the bladder. This study will look at the side effects of enfortumab vedotin alone and with other anticancer therapies. A side effect is a response to a drug that is not part of the treatment effect. This study will also test if the cancer shrinks with the different treatment combinations.

status: Recruiting

enrollment_type: Anticipated

ipd_sharing: Undecided

lead_sponsor: Astellas Pharma Global Development, Inc.

location_country:
Italy
France
Puerto Rico
Spain
United States
Canada

location_facility: Memorial Sloan Kettering Cancer Center - Monmouth

location_facility: University of Mississippi Medical Center

location_facility: Memorial Sloan Kettering Cancer Center - Basking Ridge

location_facility: Memorial Sloan Kettering Cancer Center - Westchester

location_facility: University of California, Davis Comprehensive Cancer Center

location_facility: Stanford Cancer Center / Blood & Marrow Transplant Program

location_facility: University of Colorado Hospital / University of Colorado

location_facility: UNC Lineberger Comprehensive Cancer Center / University of North Carolina

location_facility: Memorial Sloan Kettering Cancer Center - Bergen

location_facility: Tennessee Oncology / Sarah Cannon Research Institute

location_facility: Cardinal Bernardin Cancer Center / Loyola University Medical Center

location_facility: New York University (NYU) Cancer Institute

location_facility: Northwestern Medicine Cancer Center Delnor

location_facility: Northwestern Medicine Cancer Center - Warrenville / Central DuPage Hospital - Cancer Care

location_facility: Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center

location_facility: University of Michigan Comprehensive Cancer Center

location_facility: Memorial Sloan Kettering Cancer Center - Commack

location_facility: Winship Cancer Institute / Emory University School of Medicine

location_facility: Case Western Reserve University / University Hospitals Case Medical Center

location_facility: Medical College of Wisconsin (Milwaukee)

location_facility: Eastern CT Hematology and Oncology Associates

location_facility: Medical University of South Carolina/Hollings Cancer Center

location_facility: Northwell Cancer Center / Monter Cancer Center

location_facility: Texas Oncology - Fort Worth Cancer Center

location_facility: University of Texas Health Science Center at San Antonio

location_facility: Penn State Milton S. Hershey Medical Center

location_facility: Washington University School of Medicine - Siteman Cancer Center

location_facility: Memorial Sloan Kettering Cancer Center - Nassau

location_facility: Northwestern Medicine Cancer Center - Kishwaukee / Kishwaukee Cancer Center

location_facility: Boca Raton Regional Hospital / Lynn Cancer Institute

location_facility: University of California Irvine - Newport

location_facility: University of California at San Francisco

location_facility: Southcoast Centers for Cancer Care - Fairhaven Site

status_simplified: Ongoing


ReferenceCitation: Molina JM, Yazdanpanah Y, Afani Saud A, Bettacchi C, Chahin Anania C, DeJesus E, Olsen Klopfer S, Grandhi A, Eves K, Robertson MN, Correll T, Hwang C, Hanna GJ, Sklar P. Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial. Lancet HIV. 2021 Jun;8(6):e324-e333. doi: 10.1016/S2352-3018(21)00021-7. Epub 2021 May 14.

family: Molina

full_name: Jean-Michel Molina

given: Jean-Michel

family: Yazdanpanah

full_name: Yazdan Yazdanpanah

given: Yazdan

family: Afani Saud

full_name: Alejandro Afani Saud

given: Alejandro

family: Bettacchi

full_name: Christopher Bettacchi

given: Christopher

family: Chahin Anania

full_name: Carolina Chahin Anania

given: Carolina

family: DeJesus

full_name: Edwin DeJesus

given: Edwin

family: Olsen Klopfer

full_name: Stephanie Olsen Klopfer

given: Stephanie

family: Grandhi

full_name: Anjana Grandhi

given: Anjana

family: Eves

full_name: Karen Eves

given: Karen

family: Robertson

full_name: Michael N Robertson

given: Michael N

family: Correll

full_name: Todd Correll

given: Todd

family: Hwang

full_name: Carey Hwang

given: Carey

family: Hanna

full_name: George J Hanna

given: George J

family: Sklar

full_name: Peter Sklar

journal_name: The Lancet HIV

publisher: Elsevier BV

publisher_dissemination: Elsevier

publisher_group: Elsevier

publisher_normalized: Elsevier

status: Active, not recruiting

lead_sponsor: Merck Sharp & Dohme Corp.

location_country:
United States
United Kingdom
Chile
France

acronym: Dose Ranging Trial of MK-8591 Given in Combination with Doravirine (DOR) and Lamivudine (3TC)

location_facility: North Manchester General Hospital ( Site 2104)

location_facility: The Crofoot Research Center, Inc. ( Site 0118)

location_facility: Orlando Immunology Center (OIC) ( Site 0105)

location_facility: Centre Hospitalier de Tourcoing ( Site 2301)

location_facility: North Texas Infectious Diseases Consultants, PA ( Site 0103)

location_facility: University California / Davis ( Site 0101)

location_facility: Brighton and Sussex University Hospitals NHS Trust ( Site 2105)

location_facility: Hospital Dr. Hernan Henriquez Aravena ( Site 0203)

location_facility: Chelsea and Westminster Hospital ( Site 2101)

location_facility: CHU de Nice Hopital Archet 1 ( Site 2303)

location_facility: The Royal Free London NHS Foundation Trust ( Site 2102)

location_facility: Hopital Bichat - Claude Bernard ( Site 2309)

location_facility: Saint Hope Foundation, Inc. ( Site 0116)

location_facility: Tarrant County Infectious Disease Associates ( Site 0112)

source: euctr

title: A Phase 2B, Randomized, Double-Blind, Active-Comparator-Controlled, Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, Antiretroviral Activity, and Pharmacokinetics of MK-8591 Given in Combination With Doravirine (DOR) and Lamivudine (3TC) in HIV-1-Infected Treatment-Naïve Adults

summary: This study will evaluate the safety, tolerability, antiretroviral activity, and pharmacokinetics of 3 doses of islatravir (MK-8591) in combination with doravirine (DOR) and lamivudine (3TC) administered to antiretroviral treatment-naïve adult participants with human immunodeficiency virus type 1 (HIV-1) infection.


ReferenceCitation: Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Sakai H, Lingua A, Salman P, Souquet PJ, De Marchi P, Martin C, Pérol M, Scherpereel A, Lu S, John T, Carbone DP, Meadows-Shropshire S, Agrawal S, Oukessou A, Yan J, Reck M. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Feb;22(2):198-211. doi: 10.1016/S1470-2045(20)30641-0. Epub 2021 Jan 18. Erratum in: Lancet Oncol. 2021 Mar;22(3):e92.

family: Paz-Ares

full_name: Luis Paz-Ares

given: Luis

family: Ciuleanu

full_name: Tudor-Eliade Ciuleanu

given: Tudor-Eliade

family: Cobo

full_name: Manuel Cobo

given: Manuel

family: Schenker

full_name: Michael Schenker

family: Zurawski

full_name: Bogdan Zurawski

given: Bogdan

family: Menezes

full_name: Juliana Menezes

given: Juliana

family: Richardet

full_name: Eduardo Richardet

given: Eduardo

family: Bennouna

full_name: Jaafar Bennouna

given: Jaafar

family: Felip

full_name: Enriqueta Felip

given: Enriqueta

family: Juan-Vidal

full_name: Oscar Juan-Vidal

given: Oscar

family: Alexandru

full_name: Aurelia Alexandru

given: Aurelia

family: Sakai

full_name: Hiroshi Sakai

given: Hiroshi

family: Lingua

full_name: Alejo Lingua

given: Alejo

family: Salman

full_name: Pamela Salman

given: Pamela

family: Souquet

full_name: Pierre-Jean Souquet

given: Pierre-Jean

family: De Marchi

full_name: Pedro De Marchi

given: Pedro

family: Martin

full_name: Claudio Martin

given: Claudio

family: Pérol

full_name: Maurice Pérol

given: Maurice

family: Scherpereel

full_name: Arnaud Scherpereel

given: Arnaud

family: Lu

full_name: Shun Lu

given: Shun

family: John

full_name: Thomas John

given: Thomas

family: Carbone

full_name: David P Carbone

given: David P

family: Meadows-Shropshire

full_name: Stephanie Meadows-Shropshire

family: Agrawal

full_name: Shruti Agrawal

given: Shruti

family: Oukessou

full_name: Abderrahim Oukessou

given: Abderrahim

location_country:
Italy
Brazil
Chile
Mexico
Spain
Germany
France
Japan
Poland
Romania
Ireland
Belgium
Argentina
Australia
China
Russian Federation
United States
United Kingdom
Canada

location_facility: Centro de Investigacion Clinica Bradford Hill

location_facility: University of Wisconsin Carbone Cancer Center

location_facility: Mcgill University Health Center - Royal Victoria Hospital

location_facility: CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski

location_facility: Charleston Hematology Oncology Associates, Pa

location_facility: Centre Hospitalier De Saint-Brieuc Hopital Yves Le Foll

title: A Phase 3, Randomized Study of Nivolumab Plus Ipilimumab in Combination With Chemotherapy vs Chemotherapy Alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer

summary: The purpose of this study is to determine whether Nivolumab, Ipilimumab combined with chemotherapy is more effective than chemotherapy by itself when treating stage IV NSCLC as the first treatment given for the disease


intervention_type: Other

ipd_sharing_description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

lead_sponsor: Shire

location_country:
Italy
United States
Switzerland
Spain
Germany
Croatia
Czechia
France
Poland
Singapore
Hungary
Belgium
Australia
New Zealand
China
Turkey
Canada
United Kingdom
Korea, Republic of

location_facility: Complejo Asistencial Universitario de Salamanca - H. Clinico

location_facility: Hospital Universitario Germans Trias i Pujol

location_facility: Hospital Universitario Virgen de Las Nieves

location_facility: Martin Luther Universitat Halle Wittenberg

location_facility: Hospital Universitario Marques de Valdecilla

location_facility: University of Texas MD Anderson Cancer Center

location_facility: The Christie NHS Foundation Trust - PPDS

location_facility: Azienda Ospedaliera Universitaria Integrata Di Verona

location_facility: Del-pesti Centrumkorhaz- Orszagos Hematologiai és Infektologiai Intezet

location_facility: Hospital Clinico Universitario de Valencia

location_facility: Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico

location_facility: Azienda Ospedaliera Città della Salute e della Scienza di Torino

location_facility: Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego we Wroclawiu

location_facility: The First Affiliated Hospital, Zhejiang University

location_facility: Azienda Ospedaliera Universitaria Careggi

location_facility: Baskent University Medical Faculty Adana Practice and Research Center

location_facility: Joan and sandford I. Weill Medical College of Cornell University Clinic

location_facility: ICO l'Hospitalet - Hospital Duran i Reynals

location_facility: University of Maryland School of Medicine

location_facility: The First Affiliated Hospital of Soochow University

location_facility: Universitätsmedizin der Johannes Gutenberg-Universität Mainz

location_facility: Hospital Universitario Puerta de Hierro - Majadahonda

location_facility: Nanfang Hospital Southern Medical University

location_facility: Hospital Universitari i Politecnic La Fe de Valencia

location_facility: Hospital Regional Universitario de Malaga - Hospital General

location_facility: Queen Elizabeth II Health Sciences Center

location_facility: Saint Davids South Austin Medical Center

location_facility: Ankara University Medica Faculty Hematology Department Clinical Research Area PPDS

location_facility: Fondazione Policlinico Universitario A Gemelli

location_facility: VA Puget Sound Health Care System - NAVREF

location_facility: Southampton University Hospitals NHS Trust

location_facility: Hospital Universitario Vall d'Hebrón - PPDS

title: A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients

summary:
This study is about treatment options for cytomegalovirus infections in people who have received stem cell transplants. The main aim of the study is to check if the cytomegalovirus infection can no longer be detected after treatment with marivabir or valganciclovir.

Participants will take 2 tablets of marivabir or valganciclovir and 2 tablets of placebo twice a day for 8 weeks. A placebo will look like marivabir or valganciclovir but will not have any medicine in it.

After treatment, each participant will be followed up for up to 12 weeks.

Participants will visit their study clinic up to 18 times during the study.


title: A Phase 1 Multidose Study to Evaluate the Safety and Tolerability of XmAb13676 in Patients With CD20-Expressing Hematologic Malignancies

summary: The purpose of this study is to determine the safety and tolerability of intravenous (IV) administration of XmAb13676 and to determine the maximally tolerated dose (MTD) and/or recommended dose (RD).

design_allocation: Non-Randomized

ipd_sharing: No

lead_sponsor: Xencor, Inc.

location_country:
United States
France

location_facility: The Ohio State University Wexner Medical Center and James Cancer Hospital

location_facility: Centre Hospitalier Lyon-Sud, Service d'Hematologie

location_facility: UVA Health System, Division of Hematology & Oncology

location_facility: Institut Paoli Calmette Dpt of Oncology/Hematology

location_facility: CHU Haut-Leveque, Service d'Hematologie Clinique et Therapie Cellulaire

location_facility: Chu Montpellier, Hematologie Clinique St. Eloi

location_facility: Institut Universitaire du Cancer Toulouse Oncopole

location_facility: Institut Bergonie - Centre Regional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest

intervention_type: Biological


lead_sponsor: Actelion

location_country:
Italy
Austria
Switzerland
Mexico
Spain
Germany
France
Bulgaria
Czechia
Greece
Poland
Hungary
Australia
Belgium
Russian Federation
Portugal
Denmark
United States
United Kingdom
Canada

acronym: POINT

location_facility: Univ of New Mexico - Health Sciences Center

location_facility: NYU Langone Medical Center - MS Comprehensive Care Center

location_facility: Instytut Psychiatrii i Neurologii, II Klinika Neurologiczna

location_facility: Azienda Ospedaliera Universitaria (AOU) "Federico II" - Centro Regionale Per la Sclerosi Multipla c/o Clinica Neurologica II - Dipartimento di Scienze

location_facility: Azienda Ospedaliera S. Andrea di Roma - Unità Operativa Complessa di Neurologia

location_facility: Università degli Studi di Firenze - Azienda Ospedaliero Universitaria Careggi - CTO - SOD Neurologia 2

location_facility: Centro Hospitalar de São João, E.P.E. - Hospital de São João - Neurology Department

location_facility: WroMedica, J. Bielicka A. Strzałkowska SC

location_facility: Uzsoki utcai Kórház, Neurológiai Osztály

location_facility: CHRU de Lille - Hôpital Roger Salengro, Service de Neurologie

location_facility: Fakultní nemocnice u sv. Anny Brno, RS Centrum

location_facility: Axis Heilsa S. de R.L. de C.V. (Althian)

location_facility: Fondazione Istituto San Raffaele , Unità Operativa di Neurologia

location_facility: Hospital of the University of Pennsylvania

location_facility: Unidad de Investigación de Salud en Chihuahua

location_facility: Azienda Ospedaliera Universitaria Senese - Dipartimento di Scienze Neurologiche e neurosensoriali - UOSA Neurologia Sperimentale

location_facility: Hospital universitair Brussels_neurology department

location_facility: Moscow State Budgetary Healthcare Institution City Clinical Hospital No. 24 of Moscow Health Department

location_facility: Centro de Neurologia Avanzada, Neurology

location_facility: Medizinische Universität Wien, Universitätsklinik für Neurologie

location_facility: Centre Hospitalier Sud Francilien - Service de Neurologie

location_facility: "Multiprofile Hospital for Active Treatment of Neurology and Psychiatry - Sveti Naum" EAD - Neurology Clinic for Movement Disorders

location_facility: NeuroPoint GmbH, Gesellschaft für vorbeugende Gesundheitspflege

location_facility: CHU de Dijon - Hôpital François Miterrand, Service de Neurologie

location_facility: Hospital Santa Caterina - Neurology Department

location_facility: Ospedale Regionale di Lugano - Civico e Italiano, Neurologia, Lugano

location_facility: Hopital Gui de Chauliac - CHU Montpellier

location_facility: Neuro-Medic Janusz Zbrojkiewicz Poradnia Weilospecjalistyczna

location_facility: Naval Hospital of Athens - Neurology Dpt

location_facility: Neurologische Klinik und Poliklinik - Universitätsklinikum Carl Gustav Carus, Zentrum für klinische Neurowissenschaften

location_facility: Pest Megyei Flór Ferenc Kórház, Neurológia és Stroke ambulancia

location_facility: Fakultní nemocnice Hradec Králové, Neurologická klinika

location_facility: Gemeinschaftspraxis Dr. med. Joachim Springub / Wolfgang Schwarz, Studienzentrum Nord-West (Study Center)

location_facility: Universitätsklinikum Münster, Klinik für Allgemeine Neurologie

location_facility: Neurology Assoc of Ormond Beach - CNS Trials

location_facility: AOU San Martino di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DINOGMI)

location_facility: Thomas Jefferson University Hospital - Dpt Neurology MS Center

location_facility: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

location_facility: AOU Università degli Studi della Campania L. Vanvitelli - I° Policlinico - DAI di Medicina Interna e Specialistica CS, Centro Sclerosi Multipla

location_facility: IRCCS NEUROMED - Istituto Neurologico Mediterraneo - Unità Operativa di Neurologia I

location_facility: CHI POISSY-Saint Germay en Laye_Service de Neurologie et Réeducation

location_facility: University Multiprofile Hospital for Active Treatment "Sv. Ivan Rilski" EAD, Neurology Clinic

location_facility: Glostrup Hospital, Neurologisk afdelning

location_facility: Uniwersytecki Szpital Kliniczny w Bialymstoku, Klinika Neurologii i Oddziat Udarowy

location_facility: Moscow State Budgetary Healthcare Institution Filatov City Clinical Hospital No.15 of Moscow Health Department

location_facility: Nemocnice Jihlava, Neurologické oddělení

location_facility: Pardubicka krajska nemocnice, MS Centrum

location_facility: Hospital Universitario Virgen Macarena - Neurofisiology Department

location_facility: Universitätsmedizin Greifswald - Körperschaft des öffentlichen Rechts - Klinik und Poliklinik für Neurologie

location_facility: COPERNICUS - Podmiot Leczniczy Sp. z o.o.

location_facility: Queen Square MS Centre / NMR research Unit UCL Institute of Neurology

location_facility: Hospital Santa Creu I Sant Pau - Neurology Dpt

location_facility: Complejo Hospitalario Universitario de Santiago de Compostela (CHUS) - Neurology Department 2

location_facility: Zentrum für klinische Forschung Dr. med. Irma Schöll

location_facility: Aalborg Universitetshospital, Skleroseklinikken Neurologisk afdelning

location_facility: MidAmerica Neuroscience Research Foundation/Rowe Neurology

location_facility: "University Multiprofile Hospital for Active Treatment - Alexandrovska" EAD, Neurology Clinic

location_facility: 401 Military Hospital of Athens - Neurology Dept

location_facility: Aeginition Hospital - Neurology Department

location_facility: Universitätsklinikum Giessen Klinik und Poliklinik für Neurologie

location_facility: Desarrollo Ético en Investigación Clínica S.C .

location_facility: Medical Center of Athens - Neurology Dpt

location_facility: Austin Health - Neuro-Immunology Clinical Research, Education and Support Service

location_facility: Fort Wayne Neurological Center - North Office

location_facility: University Hospitals of North Midlands NHS Trust

location_facility: Hospital - Revalidatie & MS Centrum Overpelt_Neurology Department

location_facility: Azienda Ospedaliero Universitaria San Luigi Gonzaga - Centro Sclerosi Multipla CRESM

location_facility: Hôpital Universitaire Carémeau, Service de Neurologie

location_facility: Hôpital Central - CHU Nancy, Département Neurologie

location_facility: Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital

location_facility: Moscow State Budgetary Healthcare Institution Pirogov City Clinical Hospital No. 1 of Moscow Health Department

location_facility: Krajská zdravotní a.s. - Nemonice Teplice o.z., RS Centrum

location_facility: Hospital - Universitair Gent __Neurology Department

location_facility: Istituto Neurologico Carlo Besta, UOC Neurologia 4, Neuroimmunologia e Malattie Neuromuscolari, Centro Sclerosi Multipla

location_facility: Unidad de Investigacion en Salud de Chihuahua SC, Médica Sur, Unidad de Neurociencias

location_facility: Hospital de Santa Maria - Neurology Department

location_facility: State Budgetary Healthcare Institution Regional Clinical Hospital No 3

location_facility: Medizinische Hochschule Hannover, Neurologie

location_facility: Neurology Associates - MS Center of Greater Orlando

location_facility: Univeritätsspital Basel Neurologie, Neurologische Klinik und Poliklinik

title: Multicenter, Randomized, Double-blind, Parallel-group, add-on, Superiority Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)

summary: This clinical study compares the efficacy, safety, and tolerability of therapy with ponesimod vs placebo in subjects with active RMS who are treated with DMF (Tecfidera®).


title: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Severe Thrombocytopenia (Platelet Count <50,000/μL)(PACIFICA)

acronym: PACIFICA

summary:
This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) therapy in patients with MF and severe thrombocytopenia (platelet count <50,000/μL). Approximately 348 patients in total will be enrolled, randomized 2:1 to either pacritinib (approximately 232 patients) or to P/C therapy (approximately 116 patients)

Condition or disease: Primary Myelofibrosis/Post-Polycythemia Vera Myelofibrosis/ Post-essential Thrombocythemia Myelofibrosis

Intervention/treatment: Drug-Pacritinib

ReferenceCitation: Gerds AT, Savona MR, Scott BL, Talpaz M, Egyed M, Harrison CN, Yacoub A, Vannucchi A, Mead AJ, Kiladjian JJ, O'Sullivan J, García-Gutiérrez V, Bose P, Rampal RK, Miller CB, Palmer J, Oh ST, Buckley SA, Mould DR, Ito K, Tyavanagimatt S, Smith JA, Roman-Torres K, Devineni S, Craig AR, Mascarenhas JO. Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis. Blood Adv. 2020 Nov 24;4(22):5825-5835. doi: 10.1182/bloodadvances.2020003314.

name: Cleveland Clinic Taussig Cancer Institute, Cleveland OH;

family: Gerds

full_name: Aaron T. Gerds

given: Aaron T.

name: Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN;

family: Savona

full_name: Michael R. Savona

given: Michael R.

name: Fred Hutchinson Cancer Research Center, Seattle, WA;

family: Scott

full_name: Bart L. Scott

given: Bart L.

name: Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI;

family: Talpaz

full_name: Moshe Talpaz

given: Moshe

family: Egyed

full_name: Miklos Egyed

given: Miklos

name: Haematology, Guy’s and St Thomas’ National Health Service Foundation Trust, London, United Kingdom;

family: Harrison

full_name: Claire N. Harrison

given: Claire N.

name: The University of Kansas Cancer Center, Kansas City, KS;

family: Yacoub

full_name: Abdulraheem Yacoub

given: Abdulraheem

name: University of Florence, Azienda Ospedaliera-Universitaria Careggi, Florence, Italy;

family: Vannucchi

full_name: Alessandro Vannucchi

given: Alessandro

name: National Institute for Health Research Oxford Biomedical Research Centre, Medical Research Center (MRC) Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom;

family: Mead

full_name: Adam J. Mead

given: Adam J.

name: Hôpital Saint-Louis et Université Paris Diderot, Paris, France;

family: Kiladjian

full_name: Jean-Jacques Kiladjian

given: Jean-Jacques

family: O’Sullivan

full_name: Jennifer O’Sullivan

given: Jennifer

name: Ramón y Cajal Health Research Institute, University Hospital Ramón y Cajal, Madrid, Spain;

family: García-Gutiérrez

full_name: Valentin García-Gutiérrez

given: Valentin

name: University of Texas MD Anderson Cancer Center, Houston, TX;

family: Bose

full_name: Prithviraj Bose

given: Prithviraj

name: Memorial Sloan Kettering Cancer Center, New York, NY;

family: Rampal

full_name: Raajit K. Rampal

given: Raajit K.

name: Saint Agnes Cancer Institute, Baltimore, MD;

family: Miller

full_name: Carole B. Miller

given: Carole B.

family: Palmer

full_name: Jeanne Palmer

given: Jeanne

name: Washington University School of Medicine, St. Louis, MO;

family: Oh

full_name: Stephen T. Oh

given: Stephen T.

family: Buckley

full_name: Sarah A. Buckley

given: Sarah A.

name: Projections Research Inc, Phoenixville, PA; and

family: Mould

full_name: Diane R. Mould

given: Diane R.

family: Ito

full_name: Kaori Ito

given: Kaori

family: Tyavanagimatt

full_name: Shanthakumar Tyavanagimatt

given: Shanthakumar

family: Smith

full_name: Jennifer A. Smith

given: Jennifer A.

family: Roman-Torres

full_name: Karisse Roman-Torres

name: Ichan School of Medicine at Mount Sinai, New York, NY

evidence: oa repository (via OAI-PMH title and first author match)

repository_institution: Washington University School of Medicine - Digital Commons@Becker

repository_institution: University of Oxford - Oxford University Research Archive (ORA)

location_country:
Italy
United States
Serbia
Spain
Germany
France
Bulgaria
Czechia
Israel
Georgia
Poland
Hungary
Australia
Russian Federation
Belarus
Canada
United Kingdom
Korea, Republic of
Ukraine

location_facility: Hadassah Medical Center, Department of Hematology,

location_facility: Jewish General Hospital; Clinical Research Unit

location_facility: Memorial Sloan-Kettering Cancer Center- Commack

location_facility: City Clinical Hospital #4" under Dnipro City Council

location_facility: Kyiv Regional Oncology Center, Department of Hematology,

location_facility: The University of Chicago Medical Center

location_facility: LTD S.Khechinashvili University Hospital

location_facility: Malkhaz Katsiashvili Multiprofile Emergency Medicine Center LTD

location_facility: Jan Mikulicz Radecki University Hospital in Wroclaw, Department and Clinic of Hematology, Blood Neoplasms and Bone Marrow Transplantation

location_facility: Royal Hallamshire Hospital, Department of Hematology

location_facility: University Hospital Kralovske Vinohrady, Clinic of Internal Hematology

location_facility: Hospital rechts der Isar, Department of Internal Medicine III, Hematology and Oncology

location_facility: Regional Cancer Care Associates LLC - CCBD Division

location_facility: Dana Farber Cancer Institute, Massachusetts General Hospital

location_facility: Centre Hospitalier de Toulouse- Hôpital Purpan

location_facility: Fejer County St. Gyorgy University Teaching Hospital, Department of Internal Medicine I

location_facility: University of Alabama at Birmingham, (UAB) Hospital, Comprehensive Cancer Center

location_facility: Barts Health NHS Trust - The Royal London Hospital

location_facility: University of Debrecen Clinical Center (Debreceni Egyetem Klinikai Központ)

location_facility: Nasz Lekarz Medical Outpatient Clinics Slawomir Jeka

location_facility: Volgograd Regional Clinical Oncology Center

location_facility: V.D. Seredavin Samara Regional Clinical Hospital, Department of Hematology

location_facility: Specialized Hospital for Active Treatment of Hematological Diseases

location_facility: Bashkiria State Medical University, Department of Internal Medicine

location_facility: University Hospital Cologne, Department of Internal Medicine I,

location_facility: Frederic Chopin Provincial Teaching Hospital No. 1 in Rzeszow, Department of Hematology,

location_facility: Regional Clinical Hospital, Department of Hematology,

location_facility: Imperial College Healthcare NHS Trust - Hammersmith Hospital

location_facility: George Washington University-Medical Faculty Associates

location_facility: Oxford University Hospitals NHS Trust - Churchill Hospital

location_facility: Nova Scotia Health Authority, Centre for Clinical Research

location_facility: Morales Meseguer University General Hospital, Department of Hematology and Hemotherapy

location_facility: Michigan Medicine Hematology Clinic-Rogel Cancer Center

location_facility: University Polyclinic Foundation "Agostino Gemelli"

location_facility: LTD M.Zodelava's Hematology Center, Department of Hematology

location_facility: Clinical Center of Serbia, Clinic of Hematology

location_facility: The Catholic University of Korea, St. Mary's Hospital

location_facility: The University of Texas MD Anderson Cancer Center

location_facility: Communal Non-profit enterprise "Regional Center of Oncology", Department of Hematology

location_facility: University Hospital Halle (Saale), Department of Internal Medicine IV - Hematology and Oncology

location_facility: Rabin Medical Center, Clinic for Myeloproliferative Disorders

location_facility: University Clinical Hospital of Salamanca, Department of Hematology

location_facility: University Multiprofile Hospital for Active Treatment "Sveti Georgi", Plovdiv

location_facility: Nicolaus Copernicus Provincial Multispecialty Oncology and Traumatology Center in Lodz

location_facility: University Hospital Ulm, Center for Internal Medicine,

location_facility: University Clinical Hospital of Valencia, Department of Hematology and Medical Oncology

location_facility: American Oncology Partners of Maryland, PA

location_facility: Republican Research Center for Radiation Medicine and Human Ecology

location_facility: Bacs-Kiskun County Hospital, 2nd Department of Internal Medicine

location_facility: Institute of Hematology and Transfusion Medicine, Teaching Department of Hematology

location_facility: Multiprofile Hospital for Active Treatment - Sofia, part of Military Medical Academy

location_facility: Scientific Institute of Romagna for the Study and Treatment of Cancer (IRST), IRCCS

location_facility: Washington University School of Medicine-Siteman Cancer Center

location_facility: Semmelweis University SE ÁOK I. sz. Belgyógyászati Klinika

location_facility: University of Utah - Huntsman Cancer Institute

location_facility: V.A. Almazov North-West Federal Medical Research Center, Institute of Oncology and Hematology, Scientific Department of Clinical Oncology

location_facility: Rocky Mountain Cancer Centers (US Oncology/McKesson)

location_facility: S.M. Kirov Military Medical Academy, Department and Clinic for Intermediate-Level Training in Internal Medicine, Hematology Division

location_facility: Multiprofile Hospital for Active Treatment "Sveta Marina"

location_facility: Szabolcs-Szatmar-Bereg County Hospitals and University Teaching Hospital, Department of Hematology

location_facility: Cancer and Hematology Centers of Western Michigan

location_facility: Johannes Wesling Hospital Minden, Department of Oncology and Hematology

location_facility: Meir Medical Center, Hematology Institute and Blood Bank

location_facility: CHU de Nimes - Hopital Universitaire Caremeau

location_facility: The Tel Aviv Sourasky Medical Center, Department of Internal Medicine

location_facility: JSC K. Eristavi National Center For Experimental and Clinical Surgery

location_facility: Cherkasy Regional Oncology Dispensary of Cherkasy Oblast Council, Regional Treatment and Diagnostic Hematology Center, Department of Hematology

location_facility: Research Institute of Hematology and Transfusiology

location_facility: Clinical Center of Vojvodina, Clinic of Hematology

location_facility: Alfred Hospital, Malignant Hematology and Stem Cell Transplantation Service

location_facility: The Sarah Cannon Research Institute-Tennessee Oncology

location_facility: CHU Hopitaux de Bordeaux - Hôpital Haut-Lévêque

location_facility: Cancer Institute "Giovanni Paolo II", IRCCS

location_facility: Poltava M.V. Sklifosovskyi Regional Clinical Hospital under Poltava Regional Council, Department of Hematology

location_facility: Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital

location_facility: Kyiv City Clinical Hospital #9, Hematology Department #1

location_facility: Institute of Blood Pathology and Transfusion Medicine, Department of Hematology

location_facility: Tom Baker Cancer Center, Internal Medicine/Hematology

location_facility: University of Texas Health Center at San Antonio School of Medicine

location_facility: Minsk Scientific and Practical Center of Surgery, Transplantology and Hematology

location_facility: University Multiprofile Hospital for Active Treatment "Dr. Georgi Stranski"

location_facility: University of Kansas Cancer Center and Medical Pavilion

location_facility: City Clinical Hospital n.a. V.V. Veresaev of the Moscow City Health

location_facility: Lady Davis Carmel Medical Center, Department of Hematology,

location_facility: Ohio State University Comprehensive Cancer Center


ReferenceCitation: Maltais F, Ferguson GT, Feldman GJ, Deslee G, Bourdin A, Fjällbrant H, Siwek-Posłuszna A, Jenkins MA, Martin UJ. A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPD. Adv Ther. 2019 Sep;36(9):2434-2449. doi: 10.1007/s12325-019-01015-3. Epub 2019 Jul 2.

family: Maltais

full_name: François Maltais

given: François

family: Ferguson

full_name: Gary T. Ferguson

given: Gary T.

family: Feldman

full_name: Gregory J. Feldman

given: Gregory J.

family: Deslee

full_name: Gaëtan Deslee

given: Gaëtan

family: Bourdin

full_name: Arnaud Bourdin

given: Arnaud

family: Fjällbrant

full_name: Harald Fjällbrant

given: Harald

family: Siwek-Posłuszna

full_name: Agnieszka Siwek-Posłuszna

given: Agnieszka

family: Jenkins

full_name: Martin A. Jenkins

given: Martin A.

family: Martin

full_name: Ubaldo J. Martin

given: Ubaldo J.

journal_name: Advances in Therapy

publisher: Springer Science and Business Media LLC

publisher_dissemination: Springer-Nature

publisher_group: Springer-Nature

publisher_normalized: Springer

lead_sponsor: AstraZeneca

location_country:
France
Bulgaria
Hungary
Russian Federation
United States
Canada
Ukraine

acronym: AERISTO

title: A Randomised, Double-Blind, Double-Dummy, Multicentre, Parallel Group Study to Assess the Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (AERISTO)

summary: This is a phase IIIb randomised, double-blind, double-dummy, multicentre, parallel group, 24 week study to assess the efficacy and safety of Glycopyrronium/Formoterol Fumarate (GFF) fixed-dose combination 7.2/4.8 μg 2 inhalations twice daily compared to Umeclidinium/Vilanterol (UV) 62.5/25 μg fixed-dose combination 1 inhalation once daily in Patients with moderate to very severe COPD.


ReferenceType: background

ReferenceCitation: Quach H, Nooka A, Samoylova O, Venner CP, Kim K, Facon T, Spencer A, Usmani SZ, Grosicki S, Suzuki K, Delimpasi S, Weisel K, Obreja M, Zahlten-Kumeli A, Mateos MV. Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy. Br J Haematol. 2021 Aug;194(4):784-788. doi: 10.1111/bjh.17541. Epub 2021 May 28.

ReferenceCitation: Siegel D, Weisel K, Zahlten-Kumeli A, Medhekar R, Ding B, Leleu X. Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma. Leuk Lymphoma. 2021 Dec;62(12):3002-3010. doi: 10.1080/10428194.2021.1941927. Epub 2021 Jun 26.

ReferenceCitation: Suzuki K, Min CK, Kim K, Lee JJ, Shibayama H, Ko PS, Huang SY, Li SS, Ding B, Khurana M, Iida S. Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial. Int J Hematol. 2021 Dec;114(6):653-663. doi: 10.1007/s12185-021-03204-9. Epub 2021 Aug 19.

ReferenceCitation: Leleu X, Beksac M, Chou T, Dimopoulos M, Yoon SS, Prince HM, Pour L, Shelekhova T, Chari A, Khurana M, Zhang J, Obreja M, Qi M, Oriol A, Siegel D. Efficacy and safety of weekly carfilzomib (70 mg/m(2)), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies. Leuk Lymphoma. 2021 Feb;62(2):358-367. doi: 10.1080/10428194.2020.1832672. Epub 2020 Oct 28.

name: Service d'Hématologie et Thérapie cellulaire, CHU and Inserm, Poitiers, France

family: Leleu

full_name: Xavier Leleu

given: Xavier

name: Department of Hematology, Ankara University, Ankara, Turkey

family: Beksac

full_name: Meral Beksac

given: Meral

name: Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan

family: Chou

full_name: Takaaki Chou

given: Takaaki

name: Hematology and Medical Oncology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece

family: Dimopoulos

full_name: Meletios Dimopoulos

given: Meletios

name: Department of Internal Medicine, Seoul National University, Seoul, South Korea

family: Yoon

full_name: Sung-Soo Yoon

given: Sung-Soo

name: Epworth Healthcare and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia

family: Prince

full_name: H. Miles Prince

given: H. Miles

name: Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic

family: Pour

full_name: Ludek Pour

given: Ludek

name: Clinic of Professional Pathology, Saratov, Russian Federation

family: Shelekhova

full_name: Tatiana Shelekhova

given: Tatiana

name: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

family: Chari

full_name: Ajai Chari

given: Ajai

name: Clinical Development, Oncology, Amgen Inc., Thousand Oaks, CA, USA

family: Khurana

full_name: Monica Khurana

given: Monica

name: Global Biostatistical Science, Amgen Inc., Thousand Oaks, CA, USA

family: Zhang

full_name: Jianqi Zhang

given: Jianqi

family: Obreja

full_name: Mihaela Obreja

given: Mihaela

name: Hematology and Oncology, Janssen Research and Development, LLC, Spring House, PA, USA

family: Qi

full_name: Ming Qi

given: Ming

name: Institut Català d'Oncologia and Josep Carreras Research Leukaemia Institute, Hospital Germans Trias i Pujol, Barcelona, Spain

family: Oriol

full_name: Albert Oriol

given: Albert

name: John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA

family: Siegel

full_name: David Siegel

given: David

journal_name: Leukemia & Lymphoma

oa_host_type: publisher

evidence: open (via crossref license)

host_type: publisher

license: cc-by-nc-nd

license_normalized: cc-by-nc-nd

version: publishedVersion

title: Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies

ReferenceCitation: Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Yang H, Klippel Z, Zahlten-Kumeli A, Usmani SZ. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020 Jul 18;396(10245):186-197. doi: 10.1016/S0140-6736(20)30734-0. Erratum in: Lancet. 2020 Aug 15;396(10249):466.

family: Quach

full_name: Hang Quach

given: Hang

family: Mateos

full_name: Maria-Victoria Mateos

given: Maria-Victoria

family: Landgren

full_name: Ola Landgren

given: Ola

location_country:
Austria
Spain
France
Bulgaria
Czechia
Greece
Japan
Korea, Republic of
Hungary
Australia
Belgium
Poland
Romania
Russian Federation
Turkey
United States
United Kingdom
Canada
Taiwan

location_facility: Ankara Universitesi Tip Fakultesi Cebeci Hastanesi

location_facility: National Hospital Organization Kyushu Cancer Center

location_facility: Centre Hospitalier Universitaire de Nantes

location_facility: Severance Hospital Yonsei University Health System

location_facility: Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet

location_facility: University of Chicago Medical Center - Multiple Myeloma Research Consortium

location_facility: State Budget Educational Institution of High Professional Skills Samara State Medical University

location_facility: Uniwersytecki Szpital Kliniczny im Jana Mikulicza-Radeckiego we Wroclawiu

location_facility: Ziekenhuis Netwerk Antwerpen Stuivenberg

location_facility: Centre Hospitalier DÃ©partemental les Oudairies

location_facility: Centre Hospitalier Universitaire de Nancy - Hopital de Brabois

location_facility: Centre Hospitalier de Versailles - Hopital Andre Mignot

location_facility: Bekes Megyei Kozponti Korhaz Dr Rethy Pal Tagkorhaz

location_facility: SBHI of Nizhny Novgorod region Regional Clinical Hospital of Nizhny Novgorod na N A Semashko

location_facility: University Multiprofile Hospital for Active Treatment Sveti Georgi EAD

location_facility: Hospital Clinico Universitario de Salamanca

location_facility: National Hospital Organization Shibukawa Medical Center

location_facility: National Hospital Organization Okayama Medical Center

location_facility: Cancer Institute Hospital of Japanese Foundation for Cancer Research

location_facility: Chonnam National University Hwasun Hospital

location_facility: Theagenion Cancer Hospital of Thessaloniki

location_facility: Centre Hospitalier Universitaire de Poitiers - Hopital la Miletrie

location_facility: University Hospital Kyoto Prefectural University of Medicine

location_facility: The Catholic University of Korea Seoul St Marys Hospital

location_facility: Ondokuz Mayis Universitesi Tip Fakultesi

location_facility: Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im K Marcinkowskiego w Poznaniu

location_facility: New York Presbyterian Hospital, Weill Cornell Medical College

location_facility: Centrum Onkologii Ziemi Lubelskiej im Swietego Jana z Dukli

location_facility: Hospital Clinic i Provincial de Barcelona

location_facility: Specialized Hospital for Active Treatment of Hematology Diseases EAD

location_facility: Fort Wayne Medical Oncology and Hematology

location_facility: Lynn Cancer Center Boca Raton Regional Hospital, Lynn Cancer Institute

location_facility: Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont Altalanos Orvostudomanyi Kar

location_facility: Universitair Ziekenhuis Leuven - Campus Gasthuisberg

location_facility: General University Hospital of Patras Panagia i Voithia

location_facility: Emory University Winship Cancer Institute

location_facility: SBHI of Republic of Karelia Republic Hosiptal n a V A Baranov

location_facility: Spitalul Clinic Municipal Filantropia Craiova

location_facility: Hospital Universitari Germans Trias i Pujol

location_facility: Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespol Szpitali Miejskich w Chorzowie

location_facility: Profesor Dr Ion Chiricuta Institut of Oncology

location_facility: Centre Hospitalier Universitaire de Bordeaux - Hopital Haut Leveque

location_facility: Barwon Health, University Hospital Geelong

location_facility: University Multiprofile Hospital for Active Treatment Sveti Ivan Rilski EAD

location_facility: Clinic of professional pathology and hematology

location_facility: Baylor Charles A Sammons Cancer Center at Dallas

location_facility: Centre Hospitalier RÃ©gional Universitaire de Lille - HÃ´pital Claude Huriez

title: A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

summary: Compare carfizomib, dexamethasone, and daratumumab (KdD) to Carfilzomib and dexamethasone (Kd) in terms of progression free survival (PFS) in participants with multiple myeloma who have relapsed after 1 to 3 prior therapies.


ReferenceCitation: de Bono JS, Mehra N, Scagliotti GV, Castro E, Dorff T, Stirling A, Stenzl A, Fleming MT, Higano CS, Saad F, Buttigliero C, van Oort IM, Laird AD, Mata M, Chen HC, Healy CG, Czibere A, Fizazi K. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. Lancet Oncol. 2021 Sep;22(9):1250-1264. doi: 10.1016/S1470-2045(21)00376-4. Epub 2021 Aug 10.

family: de Bono

full_name: Johann S de Bono

given: Johann S

family: Mehra

full_name: Niven Mehra

given: Niven

family: Scagliotti

full_name: Giorgio V Scagliotti

given: Giorgio V

family: Castro

full_name: Elena Castro

given: Elena

family: Dorff

full_name: Tanya Dorff

given: Tanya

family: Stirling

full_name: Adam Stirling

given: Adam

family: Stenzl

full_name: Arnulf Stenzl

given: Arnulf

family: Fleming

full_name: Mark T Fleming

given: Mark T

family: Higano

full_name: Celestia S Higano

given: Celestia S

family: Saad

full_name: Fred Saad

given: Fred

family: Buttigliero

full_name: Consuelo Buttigliero

given: Consuelo

family: van Oort

full_name: Inge M van Oort

given: Inge M

family: Laird

full_name: A Douglas Laird

given: A Douglas

family: Mata

full_name: Marielena Mata

given: Marielena

family: Chen

full_name: Hsiang-Chun Chen

given: Hsiang-Chun

family: Healy

full_name: Cynthia G Healy

given: Cynthia G

family: Czibere

full_name: Akos Czibere

given: Akos

family: Fizazi

full_name: Karim Fizazi

given: Karim

journal_name: The Lancet Oncology

oa_host_type: repository

evidence: oa repository (via OAI-PMH doi match)

host_type: repository

license_normalized: no license

repository_institution: University of Turin - Institutional Research Information System University of Turin

ipd_sharing_description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

lead_sponsor: Pfizer

location_country:
Italy
Austria
Brazil
Netherlands
Germany
France
Poland
Hungary
Australia
Belgium
Spain
United States
United Kingdom
Korea, Republic of

location_facility: Szabolcs- Szatmar-Bereg Megyei Korhazak es Egyetemi Oktato Korhaz

location_facility: Clinica Universidad de Navarra-Oncology Service

location_facility: Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

location_facility: Orszagos Onkologiai Intezet, "C" Belgyogyaszati-Onkologiai es Klinikai Farmakogogiai Osztaly

location_facility: The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust , Sycamore House

location_facility: Azienda Socio Sanitaria Territoriale di Cremona (Istituti Ospitalieri di Cremona)

location_facility: Hospital Universitario Quironsalud Madrid-Oncology Service

location_facility: Weill Cornell Medical Center - New York Presbyterian Hospital

location_facility: Swietokrzyskie Centrum Onkologii Samodzielny Publiczny Zaklad Opieki Zdrowotnej

location_facility: UC Irvine Health Investigational Drug Pharmacy

location_facility: Hospital de Clinicas de Porto Alegre-HCPA

location_facility: Severance Hospital, Yonsei University Health System

location_facility: Sharp Outpatient Infusion Therapy Center

location_facility: Azienda Ospedaliero-Universitaria S. Luigi Gonzaga-SCDU Oncologia Medica

location_facility: Clinique Victor Hugo-Centre Jean Bernard

location_facility: The University of Texas Health Science Center at Tyler dba UT Health East Texas HOPE Cancer Center

location_facility: Azienda Ospedaliero Universitari di Parma - U.O. Oncologia Medica

location_facility: Intergrated Clinical Oncology Network (ICON)

location_facility: Institut de Cancerologie Strasbourg Europe

location_facility: Winship Cancer Institute, Emory University

location_facility: Washington University School of Medicine

location_facility: Szpital Specjalistyczny W Brzozowie, Podkarpacki Osrodek Onkologiczny Im.Ks.B.Markiewicza

location_facility: Azienda Ospedaliero Universitaria di Parma - U.O. Oncologia Medica

location_facility: Azienda Ospedaliera San Camillo Forlanini

location_facility: Seoul National University Bundang Hospital

location_facility: Ordensklinikum Linz, Barmherzige Schwestern

location_facility: Hospital Universitari i Politecnic La Fe

location_facility: St Vincent's Hospital Sydney, The Kinghorn Cancer Centre

location_facility: Centre Hospitalier Departemental Les Oudairies

location_facility: Weill Cornell Medical Center-New York Presbyterian Hospital

location_facility: Medical Imaging St Vincent's Hospital Sydney

location_facility: IOV - Istituto Oncologico Veneto IRCCS - U.O. Oncologia Medica 1

location_facility: Medizinische Fakultat Mannheim der Universitat Heidelberg

location_facility: Olivia Newton John Cancer Wellness & Research Centre Austin Health

location_facility: Fundacao Pio XII-Hospital de Cancer de Barretos

location_facility: Kyungpook National University Chilgok Hospital

location_facility: AULSS3 Serenissima - Ospedale dell'Angelo - Oncologia Medica

location_facility: Instituto Valenciano de Oncologia (IVO-FINCIVO)

location_facility: Swedish Cancer Institute Issaquah Campus

location_facility: University of California, Irvine Medical Center

location_facility: Azienda Ospedaliero Universitaria Citta della Salute e della Scienza di Torino

location_facility: City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

location_facility: Froedtert Hospital/Medical College of Wisconsin

location_facility: SD Oncologia Clinica Sperimentale di Uro-Ginecologia

location_facility: Hospital General Vall D'Hebron-Oncology Service

title: TALAPRO-1: A PHASE 2, OPEN-LABEL, RESPONSE RATE STUDY OF TALAZOPARIB IN MEN WITH DNA REPAIR DEFECTS AND METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO PREVIOUSLY RECEIVED TAXANE-BASED CHEMOTHERAPY AND PROGRESSED ON AT LEAST 1 NOVEL HORMONAL AGENT (ENZALUTAMIDE AND/OR ABIRATERONE ACETATE/PREDNISONE)

summary: The purpose of this international, phase 2, open-label, response rate study of talazoparib is to assess the efficacy and safety of talazoparib in men with DNA repair defects metastatic castration-resistant prostate cancer (CRPC) who previously received taxane-based chemotherapy and progressed on at least 1 novel hormonal agent (enzalutamide and/or abiraterone acetate/prednisone).


title: A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204)

summary: The purpose of this study is to evaluate the safety and efficacy of two parsaclisib treatment regimens in participants diagnosed with relapsed or refractory marginal zone lymphoma (MZL) who are naive to or were previously treated with a Bruton's tyrosine kinase (BTK) inhibitor.

lead_sponsor: Incyte Corporation

location_country:
Italy
Germany
France
Poland
Israel
Belgium
Argentina
Australia
Spain
Denmark
United States
United Kingdom

location_facility: Universitaire Ziekenhuis Leuven - Gasthuisberg

location_facility: University of Miami Sylvester Comprehensive Cancer Center

location_facility: Rabin Medical Center - Beilinson Hospital

location_facility: Centrum Onkologii-Instytut Im. Marii Sklodowskiej-Curie

location_facility: Klinika Transplantacji Komorel Krwiotworczych

location_facility: Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori

location_facility: University of Alabama At Birmingham Comprehensive Cancer Center

location_facility: Charleston Hematology Oncology Associates Pa

location_facility: Szpitale Wojew�Dzkie W Gdyni Sp�?Ka Z Ograniczon? Odpowiedzialno?Ci?

location_facility: Boca Raton Clinical Research Medical Inc.

location_facility: Hospices Civils de Lyon Centre Hospitalier Lyon Sud

location_facility: Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii

location_facility: Fondazione Irccs Istituto Nazionale Dei Tumori

location_facility: Kent Oncology Centre - Maidstone Hospital

location_facility: Hematology Oncology Associates of Rockland

location_facility: University of Washington - Seattle Cancer Care Alliance

location_facility: Rush University Medical Center - Consultants in Hematology

location_facility: Hospital General Universitari Vall D Hebron

location_facility: Hospital Universitario Quironsalud Madrid

location_facility: Centre Hospitalier Universitaire Henri Mondor

location_facility: St. Mary'S Hospital Regional Cancer Center

location_facility: COMPREHENSIVE CANCER CeNTERS OF NEVADA - TWAIN

location_facility: Ospedale Delle Croci - Ematologia Ravenna

location_facility: Azienda Ospedaliera San Gerardo Di Monza

location_facility: Robert H. Lurie Comprehensive Cancer Center of Northwestern University

location_facility: University of Bologna, Institute of Haematology �L. E A. Ser�Gnoli�

location_facility: Hadassah Hebrew University Medical Center Ein Karem Hadassah

location_facility: Azienda Ospedaliera Ospedali Riuniti "Villa Sofia - Cervello"


title: GRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease

summary: The purpose of this study is to evaluate itacitinib or placebo in combination with corticosteroids as first-line treatment of participants with Grade II to IV acute graft-versus-host disease (aGVHD).

location_country:
Italy
Austria
Switzerland
Spain
Germany
Finland
France
Czechia
Greece
Israel
Poland
Australia
Belgium
New Zealand
Portugal
United States
United Kingdom
Korea, Republic of
Taiwan

location_facility: Azienda Ospedaliero Universitaria (AOU) Policlinico - Vittorio Emanuele - Presidio Ospedaliero Ferrarotto Alessi

location_facility: Centro Hospitalar Lisboa Norte - Hospital de Santa Maria

location_facility: Hadassah Hebrew University Medical Center Ein Karem

location_facility: Hospital Universitario Marques de Valdecilla

location_facility: University of Mississippi Medical Center

location_facility: Indiana University (IU) Melvin and Bren Simon Cancer Center

location_facility: Azienda Ospedaliero Universitaria Careggi

location_facility: Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE

location_facility: C.T.M.O. Ospedale Roberto Binaghi ATS Cagliari

location_facility: A.O.U. Città della Salute e della Scienza di Torino

location_facility: Azienda Unità Sanitaria Locale di Reggio Emilia

location_facility: University of Oklahoma - Health Sciences Center

location_facility: Hospital Universitario Puerta de Hierro Majadahonda

location_facility: University of Miami - Sylvester Cancer Center

location_facility: Hospital Clinico Universitario de Valencia

location_facility: University of Florida (UF) - Division of Hematology & Oncology

location_facility: Clinica Ematologica CTA, Ospedale "San Gerardo" di Monza

location_facility: University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center

location_facility: Sarah Cannon Research Institute, LLC (SCRI)

location_facility: Hospital Clinico de Santiago de Compostela

location_facility: UHKT Prague - Institute of Hematology and Blood Transfusion

location_facility: Universtity Hospital Basel - Haematology

location_facility: Universitaet zu Koln - Universitaetsklinikum Koeln (Uniklinik Koeln)

location_facility: Universitatsklinikum Freiburg - Klinik fur Innere Medizin I

location_facility: SOC Clinica Ematologica, Azienda Ospediero-Universitaria di Udine

location_facility: Instituto Catalan de Oncologia - Hospital Duran i Reynals

location_facility: Hospital General Universitario Gregorio Maranon

location_facility: Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII

location_facility: Institut Claudius Regaud-Universitaire du Cancer Toulouse Oncopol

location_facility: University of California, Los Angeles (UCLA) - Medical Center

location_facility: General Hospital of Thessaloniki G. Papanikolaou - Hematology Department

location_facility: Universitaetsmedizin der Johannes Gutenberg

location_facility: Wake Forest Baptist Medical Center - Wake Forest University School of Medicine

location_facility: Hospital de la Santa Creu i Sant Pau - Servei de Hematologia Clinica

location_facility: Hospital Clinic i Provincial de Barcelona

location_facility: Washington University School of Medicine

location_facility: Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico di Milano

location_facility: Complejo Hospitalario Universitario de Granada - Hospital Universitario Virgen de las Nieves

location_facility: ASST Grande Ospedale Metropolitano Niguarda

location_facility: Hospital Universitari i Politecnic La Fe

location_facility: Hopital universitaire du Sart Tilman de Liege

location_facility: Oregon Health & Science University (OHSU)

location_facility: Hopital Haut Leveque - CHU Bordeaux - Maladies du sang

location_facility: University of Colorado - Aurora Cancer Center

location_facility: Azienda Ospedaliera Bianchi-Melacrino-Morelli Ospedali Riuniti

location_facility: Instituto Portugues de Oncologia de Lisboa Francisco Gentil EPE (IPO-Lisboa)

location_facility: Universitatsklinikum Hamburg - Eppendorf

location_facility: University Clinic Carl Gustav Carus, Technical University Dresden

location_facility: Advocate Lutheran General Hospital - Oncology Specialists SC

location_facility: John Theurer Cancer Center At Hackensack UMC

location_facility: Klinika Transplantacji Komorek Krwiotworczych - Instytut Hematologii i Transfuzjologii

location_facility: University Hospitals Cleveland Medical Center

location_facility: Universitaetsspital Zuerich - Klinik fuer Haematology

location_facility: General Hospital Sint-Jan Brugge-Oostend

location_facility: University of California, San Diego (UCSD) - Moores Cancer Center

location_facility: UKGM Marburg Innere Medizin: Haematologie Onkolog


title: Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Subjects With High Grade Primary CNS Malignancies

acronym: CheckMate 908

summary: The purpose of this study is to determine the safety and effectiveness of nivolumab alone and in combination with ipilimumab in pediatric patients with high grade primary central nervous system (CNS) malignancies

lead_sponsor: Bristol-Myers Squibb

location_country:
Brazil
United States
Sweden
Hong Kong
Netherlands
Germany
France
Poland
Israel
Norway
Australia
Russian Federation
Spain
Canada
United Kingdom

location_facility: Hopp Children's Cancer Center at NCT Heidelberg

location_facility: Cincinnati Children'S Hospital Medical Center

location_facility: Great Ormond Street Hospital For Children

location_facility: Prinses Maxima Centrum voor Kinderoncologie

location_facility: The Montreal Children's Hospital of the MUHC

location_facility: Klinika Onkologii Centrum Zdrowia Dziecka


title: Phase 3 Study of Ibrutinib in Combination With Venetoclax in Subjects With Mantle Cell Lymphoma

summary: This Phase 3 multinational, randomized, double-blind study is designed to compare the efficacy and safety of the combination of ibrutinib and venetoclax vs. ibrutinib and placebo in subjects with MCL.

ReferenceCitation: Wang M, Ramchandren R, Chen R, Karlin L, Chong G, Jurczak W, Wu KL, Bishton M, Collins GP, Eliadis P, Peyrade F, Lee Y, Eckert K, Neuenburg JK, Tam CS. Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study. J Hematol Oncol. 2021 Oct 30;14(1):179. doi: 10.1186/s13045-021-01188-x.

family: Wang

full_name: Michael Wang

given: Michael

family: Ramchandren

full_name: Radhakrishnan Ramchandren

given: Radhakrishnan

full_name: Robert Chen

given: Robert

family: Karlin

full_name: Lionel Karlin

given: Lionel

family: Chong

full_name: Geoffrey Chong

given: Geoffrey

family: Jurczak

full_name: Wojciech Jurczak

given: Wojciech

family: Wu

full_name: Ka Lung Wu

given: Ka Lung

family: Bishton

full_name: Mark Bishton

given: Mark

family: Collins

full_name: Graham P. Collins

given: Graham P.

family: Eliadis

full_name: Paul Eliadis

given: Paul

family: Peyrade

full_name: Frédéric Peyrade

given: Frédéric

family: Lee

full_name: Yihua Lee

given: Yihua

family: Eckert

full_name: Karl Eckert

given: Karl

family: Neuenburg

full_name: Jutta K. Neuenburg

given: Jutta K.

family: Tam

full_name: Constantine S. Tam

given: Constantine S.

currency_apc_doaj: GBP

journal_name: Journal of Hematology & Oncology

evidence: oa journal (via doaj)

license: cc-by

license_normalized: cc-by

lead_sponsor: Pharmacyclics LLC.

location_country:
Italy
United States
Netherlands
Germany
France
Czechia
Greece
Poland
Hungary
Belgium
Australia
Spain
Turkey
Canada
United Kingdom
Korea, Republic of
Ukraine

location_facility: Szpital Uniwersytecki nr 2 im. dr J. Biziela w Bydgoszcz

location_facility: Vseobecna fakultni nemocnice v Praze, l. interni klinika-klinika hematologie

location_facility: Universitatsklinikum des Saarlandes, Klinik fur Innere Medizin I

location_facility: University of Texas MD Anderson Cancer Center

location_facility: The University of Kansas Cancer Center and Medical Pavilion

location_facility: ZiekenhuisNetwerk Antwerpen (ZNA) Stuivenberg

location_facility: Andrii Novak Transcarpathian Regional Clinical Hospital, Department of Hematology

location_facility: Universitatsklinikum Essen, Klinik fur Hamatologie

location_facility: Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ

location_facility: Debreceni Egyetem Klinikai Kozpont, Belgyogyaszati Klinika

location_facility: Communal Institution O.F. Herbachevskyi Regional Clinical Hospital of Zhytomyr Regional Council Dept of Hematology with beds of Intensive Therapy

location_facility: ICO l'Hospitalet- Hospital Duran i Reynals

location_facility: Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. Kopernika w Lodzi

location_facility: Severance Hospital, Yonsei University Health System

location_facility: Institut Paoli Calmettes, Service Hematologie

location_facility: Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)

location_facility: Queen Elizabeth II Health Science Centre

location_facility: Gazi Universitesi Tip Fakultesi, Besevler

location_facility: Ondokuz Mayiz universitesi Tip Fakultesi

location_facility: Charite- Universitatsmedizin Berlin, Campus Benjamin Franklin

location_facility: Asst Grande Ospedale Metropolitano Niguarda

location_facility: Kliniken Ostalb Stauferklinikum Schwab. Gmund

location_facility: Azienda Ospedaliero Universitaria Molinette San Giovanni Battista di Torino

location_facility: Hospital Universitari Germans Trias I Pujol

location_facility: SI national Scientific Center of Radiation Medicine of NAMS of Ukraine, Dep. of Radiation Oncohematology and Stem Cell Transplantation Unit

location_facility: CHU Clermont Ferrand - Hôpital d'Estaing

location_facility: The University of Arizona Cancer Centre-North Campus

location_facility: The Catholic University of Korea, Seoul St. Mary's Hospital

location_facility: University College London Hospitals NHS Foundation Trust

location_facility: Gemeinschaftpraxis Haematologie und Onkologie

location_facility: Uniwersytecki Szpital Kliniczny im. J. Mikulicza-Radeckiego we Wroclawiu, PZOZ

location_facility: Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori

location_facility: Fakultni Nemocnice (FN) Hradec Kravlove, a.s. IV. Interni hematologicka klinika

location_facility: Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo di Alessandria

location_facility: Klinikum der Universitaet Muenchen Campus Grosshadern

location_facility: FN Brno, Interni hematologicka a onkologicka klinika

location_facility: Communal Non-profit Enterprise Regional Center of Oncology, Department of Hematology

location_facility: National Inst. of Cancer, Scientific and Research Dept of Chemotherapy of Hemoblastosis and Adjuvant Treatment Methods, Dept of Oncohematology with Sector of Adjuvant treatment methods

location_facility: Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespol Szpitali Miejskich, Oddzial Hematologiczny

location_facility: Azienda Ospedaliera S. Croce e Carle Cuneo

location_facility: Azienda Ospedaliera Universitaria di Bologna Policlinico Saint Orsola Malpighi

location_facility: Azienda Ospedaliero-Universitaria Santa Maria della Misericordia

location_facility: Nottingham University Hospitals NHS Trust

location_facility: Universitaetsmedizin der Johannes Gutenberg, Langenbeckstrasse 1

location_facility: Namik Kemal Universitesi Saglik Uyg. ve.Ars. Hastanesi

location_facility: Communal Nonprofit enterprise Cherkasy Regional Oncology Dispensary ofCherkasy Oblast Council,Regional Treatment and Diagnostic Hematological Center

location_facility: UCLA Department of Medicine-Hematology/Oncology

location_facility: Markusovszky Egyetemi Oktatokorhaz, Haematologiai es Haemoszatazeologiai Osztaly

location_facility: Petz Aladar Megyei Oktato Korhaz, II. Belgyogyaszat-Hematologia